Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an Ambulatory Elderly Population

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 480-485

  Guéant Rodriguez, Rosa Maria ^a   Spada, Rosario ^b   Moreno Garcia, Maira ^a   Anello, Guido ^b   Bosco, Paolo ^b   Lagrost, Laurent ^c   Romano, Antonino ^b   Elia, Maurizio ^b   Guéant, Jean Louis ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c Chu   (France)

Author keywords

Ankle brachial index; Folate; HDL; Homocysteine; Vitamin B12

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLMALONIC ACID; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; NORMAL HUMAN; PARTICLE SIZE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 79151482322     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.031     Document Type: Article

References (30)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-146.
2. Fowkes F.G., Housley E., Cawood E.H., et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991, 20:384-392.
3. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006, 113:e463-654.
4. Khawaja F.J., Bailey K.R., Turner S.T., et al. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin Proc 2007, 82:709-716.
5. McDermott M.M., Ferrucci L., Guralnik J.M., et al. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol 2007, 50:897-905.
6. Vidula H., Tian L., Liu K., et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008, 148:85-93.
7. Senti M., Nogues X., Pedro-Botet J., et al. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992, 85:30-36.
8. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481-2485.
9. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
10. Wald D., Law M., Morris J. Serum homocysteine and severity of coronary artery disease. Thromb Res 2003, 111:55-57.
11. Herrmann W., Herrmann M., Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007, 8:17-3112.
12. Gueant-Rodriguez R.M., Juilliere Y., Nippert M., et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J Thromb Haemost 2007, 5:1209-1216.
13. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005, 3:1646-1654.
14. Khandanpour N., Loke Y.K., Meyer F.J., et al. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2009, 38:316-322.
15. Ventura E., Durant R., Jaussent A., et al. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic Biol Med 2009, 46:737-744.
16. Woo K.S., Sanderson J.E., Sun Y.Y., et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 2000, 101:E116.
17. Liao D., Tan H., Hui R., et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006, 99:598-606.
18. Mikael L.G., Genest J., Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006, 98:564-571.
19. McDermott M.M., Liu K., Criqui M.H., et al. Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol 2005, 162:33-41.
20. Battaglia-Hsu S.F., Akchiche N., Noel N., et al. Vitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE. Proc Natl Acad Sci USA 2009, 106:21930-21935.
21. Gueant-Rodriguez R.M., Juilliere Y., Candito M., et al. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005, 94:510-515.
22. Sugiuchi H., Uji Y., Okabe H., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995, 41:717-723.
23. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
24. Lagrost L., Athias A., Herbeth B., et al. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 1996, 271:19058-19065.
25. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-Society Consensus for the Management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl. 1):S1-75.
26. Pradhan A.D., Shrivastava S., Cook N.R., et al. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 2008, 117:823-831.
27. Beers A., Haas M.J., Wong N.C., Mooradian A.D. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry 2006, 45:2408-2413.
28. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
29. Lonn E., Yusuf S., Amold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
30. Carrero J.J., Lopez-Huertas E., Salmeron L.M., et al. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005, 135:1393-1399.